GlassScriptPhysician profile
Reginald D Westmacott
NPI 1194760827
$2,594.78
in general payments reported to CMS, 2019-2025
33 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $211 · 2022: $326 · 2023: $687 · 2024: $730 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,657.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $312.23 | 2023-2025 | Orgovyx |
| Merck Sharp & Dohme LLC | $242.93 | 2020-2024 | Keytruda, Welireg, Lynparza |
| Astrazeneca Pharmaceuticals LP | $237.51 | 2019-2025 | Imfinzi, Lynparza |
| Seagen INC. | $191.87 | 2019-2023 | Tukysa |
| Pfizer INC. | $185.32 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $162.91 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $157.01 | 2019-2024 | |
| Incyte Corporation | $141.09 | 2019-2024 | Monjuvi, Jakafi, Pemazyre |
| Amgen INC. | $116.72 | 2019-2023 | Xgeva, Nplate, Vectibix |
| Janssen Biotech, INC. | $106.64 | 2019-2024 | Tecvayli, Darzalex, Talvey |
| Regeneron Healthcare Solutions, INC. | $89.09 | 2023-2024 | Libtayo |
| Pharmacosmos Therapeutics INC. | $78.44 | 2024 | Monoferric |
| Abbvie INC. | $71.59 | 2019-2024 | Lupron Depot |
| Lilly USA, LLC | $56.53 | 2023-2024 | Jaypirca, Verzenio, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $53.69 | 2024 | Iclusig, Fruzaqla |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| C. R. Bard, INC. & Subsidiaries | $46.59 | 2023 | Bard Urinary Drainage Bag |
| Genmab U.S., INC. | $30.32 | 2024 | Epkinly |
| Ipsen Biopharmaceuticals, INC | $29.59 | 2019-2024 | Onivyde |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.45 | 2023 | Gilotrif |
| Mylan Institutional INC. | $27.15 | 2023 | Fulphila, Ogivri |
| Jazz Pharmaceuticals INC. | $25.56 | 2023 | |
| Myovant Sciences INC. | $23.92 | 2022 | |
| Rochester Medical Corporation | $21.80 | 2022 | |
| Puma Biotechnology, INC. | $20.95 | 2024 | |
| Aveo Pharmaceuticals, INC. | $19.65 | 2024 | |
| Alexion Pharmaceuticals, INC. | $18.70 | 2019 | |
| Genzyme Corporation | $18.34 | 2023 | |
| Eusa Pharma (US) LLC | $15.20 | 2022 | |
| Tempus Ai, INC | $14.58 | 2025 | Xt Cdx |
| Adaptive Biotechnologies Corporation | $14.15 | 2025 | Clonoseq |
| Emd Serono, INC. | $12.93 | 2019 | |
| Rigel Pharmaceuticals, INC. | $12.47 | 2023 | Tavalisse, Rezlidhia |
| Janssen Pharmaceuticals, INC | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reginald Westmacott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.